<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="90791">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01999153</url>
  </required_header>
  <id_info>
    <org_study_id>2012/119/HP</org_study_id>
    <nct_id>NCT01999153</nct_id>
  </id_info>
  <brief_title>Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site</brief_title>
  <acronym>ROPI</acronym>
  <official_title>Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to Evaluate of the analgesic effect of ropivacaine in topical use at
      the thin skin graft donor site.

      For Patient needing a thin skin graft &lt; 320 cm2, randomization will be done in 2 groups, one
      receiving the standard treatment (20 mL of physiologic serum) during the surgical
      intervention in topical use to recover an alginate dressing (Algosteril)and the other
      receive 20 mL of Naropein during the surgical intervention on alginate dressing.

      The hypothesis of the study is the administration of ropivacaine will decrease the
      post-operative pain compared to physiologic serum
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Class II analgesic consumption between the 2 arms</measure>
    <time_frame>5 days post-operative</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the effect of ropivacaine in topical use on an alginate dressing by evaluating the use of class II analgesic medicines in patient who had a thin skin graft</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Class II antalgic consumption between the 2 arms</measure>
    <time_frame>Day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>evaluate the effect of ropivacaine on postoperative pain at the skin graft donor site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>day 90</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>potential side effects of ropivacaine on the healing of skin graft donor site</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Graft Pain</condition>
  <arm_group>
    <arm_group_label>DRUG : ROPIVACAINE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mL topically used during alginate dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO : NaCl 0.9 %</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 mL topically used during alginate dressing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mL topically used during alginate dressing  NAROPEINE</intervention_name>
    <description>20 mL topically used during alginate dressing</description>
    <arm_group_label>DRUG : ROPIVACAINE</arm_group_label>
    <other_name>Brand name of drug use NAROPEINE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mL topically used during alginate dressing NaCl</intervention_name>
    <description>20 mL topically used during alginate dressing</description>
    <arm_group_label>PLACEBO : NaCl 0.9 %</arm_group_label>
    <other_name>NaCl 0.9 %</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient older than 18 years old

          -  Patient needing a thin skin graft &lt; 320 cm2 and which is possible on the thigh

          -  Patient who read the information letter and signed  the informed consent

          -  Patient affiliated at a social security system

          -  Effective contraceptive method for more than 3 months for women of childbearing age

        Exclusion Criteria:

          -  Contraindication to one of the medicine used (allergy, intolerance, potential drug
             interaction)

          -  Treatment by classII or III of analgesics or analgesic dose of aspirin(&gt;500mg per
             day) at the inclusion or randomization time

          -  Preoperative EVA&gt;0 at the skin graft donor site on the thigh

          -  Sensory disturbances of the lower limbs

          -  Cognitive disturbances not allowing investigations

          -  Pregnant or lactating women

          -  People deprived of discernment

          -  People deprived of their liberty by judicial or administrative authority

          -  Protected adult (guardianship or trusteeship)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothée COQUEREL-BEGHIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Rouen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dorothée COQUEREL, MD</last_name>
    <phone>+33232888760</phone>
    <email>dorothee.coquerel-beghin@chu-rouen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UHRouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dorothée COQUEREL-BEGHIN, Md</last_name>
      <phone>+33232888760</phone>
      <email>dorothee.coquerel-beghin@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Dorothée COQUEREL-BEGHIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>July 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>skin graft</keyword>
  <keyword>donor site</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alginic acid</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
